GLAXF - GlaxoSmithKline plc
Other OTC - Other OTC Delayed price. Currency in USD
Show:
Annual
Income statement
Currency in GBP. All numbers in thousandsBreakdown
ttm
30/12/2018
30/12/2017
30/12/2016
30/12/2015
Total revenue
31,759,000
30,821,000
30,186,000
27,889,000
23,923,000
Cost of revenue
10,910,000
10,241,000
10,342,000
9,290,000
8,853,000
Gross profit
20,849,000
20,580,000
19,844,000
18,599,000
15,070,000
Operating expenses
Research development
4,183,000
3,893,000
4,476,000
3,628,000
3,560,000
Selling general and administrative
10,214,000
9,915,000
9,672,000
9,366,000
9,232,000
Total operating expenses
12,892,000
13,516,000
13,783,000
12,573,000
4,748,000
Operating income or loss
7,957,000
7,064,000
6,061,000
6,026,000
10,322,000
Interest expense
861,000
756,000
720,000
701,000
757,000
Total other income/expenses net
-
-
-
5,000
857,000
Income before tax
5,638,000
4,800,000
3,525,000
1,939,000
10,526,000
Income tax expense
791,000
754,000
1,356,000
877,000
2,154,000
Income from continuing operations
4,847,000
4,046,000
2,169,000
1,062,000
8,372,000
Net income
4,427,000
3,623,000
1,532,000
912,000
8,422,000
Net Income available to common shareholders
4,427,000
3,623,000
1,532,000
912,000
8,422,000
Reported EPS
Basic
-
0.74
0.31
0.19
1.74
Diluted
-
0.73
0.31
0.19
1.72
Weighted average shares outstanding
Basic
-
4,914,000
4,886,000
4,860,000
4,831,000
Diluted
-
4,971,000
4,941,000
4,909,000
4,888,000
EBITDA
-
7,412,000
6,167,000
4,414,000
13,145,000